{"id":"https://openalex.org/W1904205116","doi":"https://doi.org/10.1200/jco.2013.31.15_suppl.4505","title":"Clinical activity, safety, and biomarkers of MPDL3280A, an engineered PD-L1 antibody in patients with metastatic renal cell carcinoma (mRCC).","display_name":"Clinical activity, safety, and biomarkers of MPDL3280A, an engineered PD-L1 antibody in patients with metastatic renal cell carcinoma (mRCC).","publication_year":2013,"publication_date":"2013-05-20","ids":{"openalex":"https://openalex.org/W1904205116","doi":"https://doi.org/10.1200/jco.2013.31.15_suppl.4505","mag":"1904205116"},"language":"en","primary_location":{"id":"doi:10.1200/jco.2013.31.15_suppl.4505","doi":"https://doi.org/10.1200/jco.2013.31.15_suppl.4505","is_oa":false,"landing_page_url":"https://doi.org/10.1200/jco.2013.31.15_suppl.4505","pdf_url":null,"source":{"id":"https://openalex.org/S15137598","display_name":"Journal of Clinical Oncology","issn_l":"0732-183X","issn":["0732-183X","1527-7755"],"is_oa":false,"is_in_doaj":false,"is_core":true,"listed_in":["anvur-scientific","cwts-core","dongbi-a","doyens","jufo-3","ki-jl-3","medline","norway-2","poland-200","russia-white-list-1","vabb-shw"],"host_organization":"https://openalex.org/P4310315671","host_organization_name":"Lippincott Williams & Wilkins","host_organization_lineage":["https://openalex.org/P4310315671","https://openalex.org/P4310318547"],"host_organization_lineage_names":["Lippincott Williams & Wilkins","Wolters Kluwer"],"type":"journal"},"license":null,"license_id":null,"version":"publishedVersion","is_accepted":true,"is_published":true,"raw_source_name":"Journal of Clinical Oncology","raw_type":"journal-article"},"volume":null,"type":"conference-abstract","is_traditional":false,"indexed_in":["crossref"],"open_access":{"is_oa":false,"oa_status":"closed","oa_url":null,"any_repository_has_fulltext":false},"authorships":[{"author_position":"first","author":{"id":"https://openalex.org/A5083614176","display_name":"Daniel C. Cho","orcid":"https://orcid.org/0000-0002-4248-6382","observed_orcids":["https://orcid.org/0000-0002-4248-6382"]},"institutions":[{"id":"https://openalex.org/I1316535847","display_name":"Beth Israel Deaconess Medical Center","ror":"https://ror.org/04drvxt59","country_code":"US","type":"healthcare","lineage":["https://openalex.org/I1316535847"]}],"countries":["US"],"is_corresponding":false,"raw_author_name":"Daniel C. Cho","raw_affiliation_strings":["Beth Israel Deaconess Medical Center, Boston, MA"],"raw_orcid":null,"affiliations":[{"raw_affiliation_string":"Beth Israel Deaconess Medical Center, Boston, MA","institution_ids":["https://openalex.org/I1316535847"]}]},{"author_position":"middle","author":{"id":"https://openalex.org/A5075566772","display_name":"Jeffrey Alan Sosman","orcid":"https://orcid.org/0000-0002-0650-9698","observed_orcids":["https://orcid.org/0000-0002-0650-9698"]},"institutions":[{"id":"https://openalex.org/I901861585","display_name":"Vanderbilt University Medical Center","ror":"https://ror.org/05dq2gs74","country_code":"US","type":"healthcare","lineage":["https://openalex.org/I4210162197","https://openalex.org/I901861585"]}],"countries":["US"],"is_corresponding":false,"raw_author_name":"Jeffrey Alan Sosman","raw_affiliation_strings":["Vanderbilt University Medical Center, Nashville, TN"],"raw_orcid":null,"affiliations":[{"raw_affiliation_string":"Vanderbilt University Medical Center, Nashville, TN","institution_ids":["https://openalex.org/I901861585"]}]},{"author_position":"middle","author":{"id":"https://openalex.org/A5007198397","display_name":"Mario Sznol","orcid":"https://orcid.org/0000-0003-4137-9662","observed_orcids":["https://orcid.org/0000-0003-4137-9662"]},"institutions":[{"id":"https://openalex.org/I32971472","display_name":"Yale University","ror":"https://ror.org/03v76x132","country_code":"US","type":"education","lineage":["https://openalex.org/I32971472"]}],"countries":["US"],"is_corresponding":false,"raw_author_name":"Mario Sznol","raw_affiliation_strings":["Yale University, New Haven, CT"],"raw_orcid":null,"affiliations":[{"raw_affiliation_string":"Yale University, New Haven, CT","institution_ids":["https://openalex.org/I32971472"]}]},{"author_position":"middle","author":{"id":"https://openalex.org/A5069690249","display_name":"Michael S. Gordon","orcid":"https://orcid.org/0000-0002-7679-9504","observed_orcids":["https://orcid.org/0000-0002-7679-9504"]},"institutions":[{"id":"https://openalex.org/I4210146652","display_name":"Pinnacle Oncology Hematology","ror":"https://ror.org/043rqx383","country_code":"US","type":"healthcare","lineage":["https://openalex.org/I4210146652"]}],"countries":["US"],"is_corresponding":false,"raw_author_name":"Michael S. Gordon","raw_affiliation_strings":["Pinnacle Oncology Hematology, Scottsdale, AZ"],"raw_orcid":null,"affiliations":[{"raw_affiliation_string":"Pinnacle Oncology Hematology, Scottsdale, AZ","institution_ids":["https://openalex.org/I4210146652"]}]},{"author_position":"middle","author":{"id":"https://openalex.org/A5086593040","display_name":"Antoine Hollebecque","orcid":"https://orcid.org/0000-0003-2869-7551","observed_orcids":["https://orcid.org/0000-0003-2869-7551"]},"institutions":[{"id":"https://openalex.org/I2801843802","display_name":"Institut Gustave Roussy","ror":"https://ror.org/0321g0743","country_code":"FR","type":"facility","lineage":["https://openalex.org/I2801843802"]}],"countries":["FR"],"is_corresponding":false,"raw_author_name":"Antoine Hollebecque","raw_affiliation_strings":["Institut Gustave Roussy, Villejuif, France"],"raw_orcid":null,"affiliations":[{"raw_affiliation_string":"Institut Gustave Roussy, Villejuif, France","institution_ids":["https://openalex.org/I2801843802"]}]},{"author_position":"middle","author":{"id":"https://openalex.org/A5028592995","display_name":"Omid Hamid","orcid":"https://orcid.org/0000-0002-8238-4655","observed_orcids":["https://orcid.org/0000-0002-8238-4655"]},"institutions":[{"id":"https://openalex.org/I4210104507","display_name":"Angeles Clinic and Research Institute","ror":"https://ror.org/01ct2ab72","country_code":"US","type":"healthcare","lineage":["https://openalex.org/I1282927834","https://openalex.org/I4210104507"]}],"countries":["US"],"is_corresponding":false,"raw_author_name":"Omid Hamid","raw_affiliation_strings":["The Angeles Clinic and Research Institute, Los Angeles, CA"],"raw_orcid":null,"affiliations":[{"raw_affiliation_string":"The Angeles Clinic and Research Institute, Los Angeles, CA","institution_ids":["https://openalex.org/I4210104507"]}]},{"author_position":"middle","author":{"id":"https://openalex.org/A5007052233","display_name":"David F. McDermott","orcid":"https://orcid.org/0000-0002-2675-5095","observed_orcids":["https://orcid.org/0000-0002-2675-5095","https://orcid.org/0000-0001-6978-0867"]},"institutions":[{"id":"https://openalex.org/I4210117453","display_name":"Dana-Farber Cancer Institute","ror":"https://ror.org/02jzgtq86","country_code":"US","type":"facility","lineage":["https://openalex.org/I4210117453"]}],"countries":["US"],"is_corresponding":false,"raw_author_name":"David F. McDermott","raw_affiliation_strings":["Dana-Farber Cancer Institute, Boston, MA","Dana-Farber Cancer Institute, Boston, MA#TAB#"],"raw_orcid":null,"affiliations":[{"raw_affiliation_string":"Dana-Farber Cancer Institute, Boston, MA","institution_ids":["https://openalex.org/I4210117453"]},{"raw_affiliation_string":"Dana-Farber Cancer Institute, Boston, MA#TAB#","institution_ids":["https://openalex.org/I4210117453"]}]},{"author_position":"middle","author":{"id":"https://openalex.org/A5028020706","display_name":"Jean\u2010Pierre Delord","orcid":"https://orcid.org/0000-0001-7305-5561","observed_orcids":["https://orcid.org/0000-0001-7305-5561"]},"institutions":[{"id":"https://openalex.org/I4210128666","display_name":"Institut Claudius Regaud","ror":"https://ror.org/03pa87f90","country_code":"FR","type":"healthcare","lineage":["https://openalex.org/I4210128666"]}],"countries":["FR"],"is_corresponding":false,"raw_author_name":"Jean-Pierre Delord","raw_affiliation_strings":["Institut Claudius Regaud, Toulouse, France"],"raw_orcid":null,"affiliations":[{"raw_affiliation_string":"Institut Claudius Regaud, Toulouse, France","institution_ids":["https://openalex.org/I4210128666"]}]},{"author_position":"middle","author":{"id":"https://openalex.org/A5047573588","display_name":"Ina Park Rhee","orcid":null,"observed_orcids":[]},"institutions":[{"id":"https://openalex.org/I183934855","display_name":"Genentech","ror":"https://ror.org/04gndp242","country_code":"US","type":"company","lineage":["https://openalex.org/I118019719","https://openalex.org/I129302853","https://openalex.org/I183934855"]}],"countries":["US"],"is_corresponding":false,"raw_author_name":"Ina Park Rhee","raw_affiliation_strings":["Genentech Inc., South San Francisco, CA"],"raw_orcid":null,"affiliations":[{"raw_affiliation_string":"Genentech Inc., South San Francisco, CA","institution_ids":["https://openalex.org/I183934855"]}]},{"author_position":"middle","author":{"id":"https://openalex.org/A5079272191","display_name":"Ahmad Mokatrin","orcid":null,"observed_orcids":[]},"institutions":[{"id":"https://openalex.org/I183934855","display_name":"Genentech","ror":"https://ror.org/04gndp242","country_code":"US","type":"company","lineage":["https://openalex.org/I118019719","https://openalex.org/I129302853","https://openalex.org/I183934855"]}],"countries":["US"],"is_corresponding":false,"raw_author_name":"Ahmad Mokatrin","raw_affiliation_strings":["Genentech, Inc., South San Francisco, CA"],"raw_orcid":null,"affiliations":[{"raw_affiliation_string":"Genentech, Inc., South San Francisco, CA","institution_ids":["https://openalex.org/I183934855"]}]},{"author_position":"middle","author":{"id":"https://openalex.org/A5001204975","display_name":"Marcin Kowanetz","orcid":null,"observed_orcids":[]},"institutions":[{"id":"https://openalex.org/I183934855","display_name":"Genentech","ror":"https://ror.org/04gndp242","country_code":"US","type":"company","lineage":["https://openalex.org/I118019719","https://openalex.org/I129302853","https://openalex.org/I183934855"]}],"countries":["US"],"is_corresponding":false,"raw_author_name":"Marcin Kowanetz","raw_affiliation_strings":["Genentech, Inc., South San Francisco, CA"],"raw_orcid":null,"affiliations":[{"raw_affiliation_string":"Genentech, Inc., South San Francisco, CA","institution_ids":["https://openalex.org/I183934855"]}]},{"author_position":"middle","author":{"id":"https://openalex.org/A5111904241","display_name":"Roel Peter Funke","orcid":null,"observed_orcids":[]},"institutions":[{"id":"https://openalex.org/I183934855","display_name":"Genentech","ror":"https://ror.org/04gndp242","country_code":"US","type":"company","lineage":["https://openalex.org/I118019719","https://openalex.org/I129302853","https://openalex.org/I183934855"]}],"countries":["US"],"is_corresponding":false,"raw_author_name":"Roel Peter Funke","raw_affiliation_strings":["Genentech Inc., South San Francisco, CA"],"raw_orcid":null,"affiliations":[{"raw_affiliation_string":"Genentech Inc., South San Francisco, CA","institution_ids":["https://openalex.org/I183934855"]}]},{"author_position":"middle","author":{"id":"https://openalex.org/A5066541232","display_name":"Gregg Daniel Fine","orcid":null,"observed_orcids":[]},"institutions":[{"id":"https://openalex.org/I183934855","display_name":"Genentech","ror":"https://ror.org/04gndp242","country_code":"US","type":"company","lineage":["https://openalex.org/I118019719","https://openalex.org/I129302853","https://openalex.org/I183934855"]}],"countries":["US"],"is_corresponding":false,"raw_author_name":"Gregg Daniel Fine","raw_affiliation_strings":["Genentech, Inc., South San Francisco, CA"],"raw_orcid":null,"affiliations":[{"raw_affiliation_string":"Genentech, Inc., South San Francisco, CA","institution_ids":["https://openalex.org/I183934855"]}]},{"author_position":"last","author":{"id":"https://openalex.org/A5089861374","display_name":"Thomas B. Powles","orcid":"https://orcid.org/0000-0001-7760-4724","observed_orcids":["https://orcid.org/0000-0001-7760-4724"]},"institutions":[{"id":"https://openalex.org/I166337079","display_name":"Queen Mary University of London","ror":"https://ror.org/026zzn846","country_code":"GB","type":"education","lineage":["https://openalex.org/I124357947","https://openalex.org/I166337079"]},{"id":"https://openalex.org/I225661044","display_name":"Barts Health NHS Trust","ror":"https://ror.org/00b31g692","country_code":"GB","type":"healthcare","lineage":["https://openalex.org/I225661044"]},{"id":"https://openalex.org/I4405264518","display_name":"Barts Cancer Institute","ror":"https://ror.org/0266wrt04","country_code":"GB","type":"education","lineage":["https://openalex.org/I124357947","https://openalex.org/I166337079","https://openalex.org/I4405264518"]}],"countries":["GB"],"is_corresponding":false,"raw_author_name":"Thomas Powles","raw_affiliation_strings":["Barts Cancer Institute, QMUL, Barts Health NHS Trust, London, United Kingdom"],"raw_orcid":null,"affiliations":[{"raw_affiliation_string":"Barts Cancer Institute, QMUL, Barts Health NHS Trust, London, United Kingdom","institution_ids":["https://openalex.org/I166337079","https://openalex.org/I225661044","https://openalex.org/I4405264518"]}]}],"institutions":[],"countries_distinct_count":3,"institutions_distinct_count":12,"corresponding_author_ids":[],"corresponding_institution_ids":[],"apc_list":null,"apc_paid":null,"fwci":null,"has_fulltext":false,"cited_by_count":97,"citation_normalized_percentile":null,"cited_by_percentile_year":null,"biblio":{"volume":"31","issue":"15_suppl","first_page":"4505","last_page":"4505"},"is_retracted":false,"is_paratext":false,"is_xpac":false,"primary_topic":{"id":"https://openalex.org/T10158","display_name":"Cancer Immunotherapy and Biomarkers","score":0.9702000021934509,"subfield":{"id":"https://openalex.org/subfields/2730","display_name":"Oncology"},"field":{"id":"https://openalex.org/fields/27","display_name":"Medicine"},"domain":{"id":"https://openalex.org/domains/4","display_name":"Health Sciences"}},"topics":[{"id":"https://openalex.org/T10158","display_name":"Cancer Immunotherapy and Biomarkers","score":0.9702000021934509,"subfield":{"id":"https://openalex.org/subfields/2730","display_name":"Oncology"},"field":{"id":"https://openalex.org/fields/27","display_name":"Medicine"},"domain":{"id":"https://openalex.org/domains/4","display_name":"Health Sciences"}},{"id":"https://openalex.org/T10449","display_name":"Renal cell carcinoma treatment","score":0.027499999850988388,"subfield":{"id":"https://openalex.org/subfields/2730","display_name":"Oncology"},"field":{"id":"https://openalex.org/fields/27","display_name":"Medicine"},"domain":{"id":"https://openalex.org/domains/4","display_name":"Health Sciences"}},{"id":"https://openalex.org/T11297","display_name":"Ferroptosis and cancer prognosis","score":0.00019999999494757503,"subfield":{"id":"https://openalex.org/subfields/1306","display_name":"Cancer Research"},"field":{"id":"https://openalex.org/fields/13","display_name":"Biochemistry, Genetics and Molecular Biology"},"domain":{"id":"https://openalex.org/domains/1","display_name":"Life Sciences"}}],"keywords":[{"id":"https://openalex.org/keywords/atezolizumab","display_name":"atezolizumab","score":0.9950000047683716},{"id":"https://openalex.org/keywords/pembrolizumab","display_name":"pembrolizumab","score":0.8550000190734863},{"id":"https://openalex.org/keywords/pd-l1-blockade","display_name":"PD-L1 blockade","score":0.7720000147819519},{"id":"https://openalex.org/keywords/metastatic-renal-cell-carcinoma","display_name":"metastatic renal cell carcinoma","score":0.9810000061988831},{"id":"https://openalex.org/keywords/immune-checkpoint-inhibitors","display_name":"immune checkpoint inhibitors","score":0.6620000004768372},{"id":"https://openalex.org/keywords/treatment-safety","display_name":"treatment safety","score":0.48399999737739563},{"id":"https://openalex.org/keywords/adverse-events","display_name":"adverse events","score":0.824999988079071},{"id":"https://openalex.org/keywords/hypophosphatemia","display_name":"hypophosphatemia","score":0.7990000247955322},{"id":"https://openalex.org/keywords/myasthenia-gravis","display_name":"myasthenia gravis","score":0.8130000233650208},{"id":"https://openalex.org/keywords/pd-l1-expression","display_name":"PD-L1 expression","score":0.628000020980835},{"id":"https://openalex.org/keywords/tumor-infiltrating-lymphocytes","display_name":"tumor-infiltrating lymphocytes","score":0.6759999990463257}],"concepts":[{"id":"https://openalex.org/C71924100","wikidata":"https://www.wikidata.org/wiki/Q11190","display_name":"Medicine","level":0,"score":0.94793701171875},{"id":"https://openalex.org/C2777472916","wikidata":"https://www.wikidata.org/wiki/Q1164529","display_name":"Renal cell carcinoma","level":2,"score":0.6966633200645447},{"id":"https://openalex.org/C126322002","wikidata":"https://www.wikidata.org/wiki/Q11180","display_name":"Internal medicine","level":1,"score":0.6310173869132996},{"id":"https://openalex.org/C2779524853","wikidata":"https://www.wikidata.org/wiki/Q1284347","display_name":"Pneumonitis","level":3,"score":0.6052197217941284},{"id":"https://openalex.org/C197934379","wikidata":"https://www.wikidata.org/wiki/Q2047938","display_name":"Adverse effect","level":2,"score":0.4675893485546112},{"id":"https://openalex.org/C90924648","wikidata":"https://www.wikidata.org/wiki/Q120569","display_name":"Gastroenterology","level":1,"score":0.441927969455719},{"id":"https://openalex.org/C143998085","wikidata":"https://www.wikidata.org/wiki/Q162555","display_name":"Oncology","level":1,"score":0.3409920632839203},{"id":"https://openalex.org/C2777714996","wikidata":"https://www.wikidata.org/wiki/Q7886","display_name":"Lung","level":2,"score":0.1871110498905182}],"mesh":[],"locations_count":1,"locations":[{"id":"doi:10.1200/jco.2013.31.15_suppl.4505","doi":"https://doi.org/10.1200/jco.2013.31.15_suppl.4505","is_oa":false,"landing_page_url":"https://doi.org/10.1200/jco.2013.31.15_suppl.4505","pdf_url":null,"source":{"id":"https://openalex.org/S15137598","display_name":"Journal of Clinical Oncology","issn_l":"0732-183X","issn":["0732-183X","1527-7755"],"is_oa":false,"is_in_doaj":false,"is_core":true,"listed_in":["anvur-scientific","cwts-core","dongbi-a","doyens","jufo-3","ki-jl-3","medline","norway-2","poland-200","russia-white-list-1","vabb-shw"],"host_organization":"https://openalex.org/P4310315671","host_organization_name":"Lippincott Williams & Wilkins","host_organization_lineage":["https://openalex.org/P4310315671","https://openalex.org/P4310318547"],"host_organization_lineage_names":["Lippincott Williams & Wilkins","Wolters Kluwer"],"type":"journal"},"license":null,"license_id":null,"version":"publishedVersion","is_accepted":true,"is_published":true,"raw_source_name":"Journal of Clinical Oncology","raw_type":"journal-article"}],"best_oa_location":null,"sustainable_development_goals":[{"id":"https://metadata.un.org/sdg/3","score":1.0,"display_name":"Good health and well-being"}],"study_designs":[],"awards":[],"funders":[],"has_content":{"pdf":false,"grobid_xml":false},"content_urls":null,"referenced_works_count":0,"referenced_works":[],"related_works":["https://openalex.org/W2211875475","https://openalex.org/W2494402106","https://openalex.org/W1829526068","https://openalex.org/W1766682057","https://openalex.org/W2204966689","https://openalex.org/W2941091825","https://openalex.org/W2332229267","https://openalex.org/W2999628658","https://openalex.org/W2530956073","https://openalex.org/W2233818050"],"abstract_inverted_index":{"4505":[0],"Background:":[1],"Human":[2],"RCC":[3,83,165,228,260,329],"expresses":[4],"PD-L1":[5,33,287],"and":[6,28,40,89,100,120,140,176,289,334],"has":[7],"been":[8,326],"shown":[9],"to":[10,12,25,67,190,207,213,232,266,321],"respond":[11],"immune-based":[13],"therapy.":[14,144,215],"MPDL3280A,":[15],"a":[16,57,107,151,201,284],"human":[17],"monoclonal":[18],"antibody":[19],"containing":[20],"an":[21],"engineered":[22],"Fc-domain":[23],"designed":[24],"optimize":[26],"efficacy":[27],"safety,":[29],"targets":[30],"PD-L1,":[31],"blocking":[32],"from":[34,279],"binding":[35],"its":[36],"receptors,":[37],"including":[38,242],"PD-1":[39],"B7.1.":[41],"Methods:":[42],"Pts":[43,62,145],"with":[44,148,172,249,295,312,319,332],"mRCC":[45],"received":[46,130,135,138,142,146],"MPDL3280A":[47,149,308,333],"administered":[48],"IV":[49],"q3w":[50],"at":[51,91,253],"doses":[52,92],"between":[53,286],"3-20":[54],"mg/kg":[55,102],"in":[56,164,200,299,328],"Phase":[58],"I":[59],"expansion":[60],"study.":[61],"were":[63,85,117,188,236,244],"treated":[64,90,331],"for":[65,87,150,238],"up":[66],"1":[68,193],"y.":[69],"Response":[70],"was":[71,167,198,204,221,273,309],"assessed":[72],"by":[73],"RECIST":[74,240,268],"v1.1.":[75],"Results:":[76],"As":[77],"of":[78,93,110,127,154,161,170,185,195,256,276],"Jan":[79],"10,":[80],"2013,":[81],"53":[82],"pts":[84,105,128,166,229,261,330],"evaluable":[86,237],"safety":[88],"3":[94],"(n=2),":[95],"10":[96],"(n=12),":[97],"15":[98],"(n=18)":[99],"20":[101],"(n=21).":[103],"These":[104],"had":[106,122,123,129],"median":[108,152],"age":[109],"62":[111],"y":[112],"(range":[113,157],"33-79":[114],"y),":[115],"100%":[116],"PS":[118],"0-1":[119],"all":[121,250],"prior":[124,131,212,231,265],"surgery.":[125],"83%":[126],"systemic":[132],"therapy;":[133],"38%":[134],"immunotherapy,":[136],"57%":[137],"TKIs":[139],"36%":[141],"anti-angiogenic":[143],"treatment":[147],"duration":[153],"190":[155],"days":[156],"21-317).":[158],"The":[159,270],"incidence":[160],"G3/4":[162,186],"AEs":[163,187],"43%,":[168],"regardless":[169],"attribution,":[171],"hypophosphatemia,":[173],"fatigue,":[174],"dyspnea":[175],"hyperglycemia":[177],"(all":[178],"4%)":[179],"being":[180],"the":[181,254],"most":[182],"common.":[183],"13%":[184],"attributable":[189],"study":[191,336],"drug.":[192],"case":[194],"myasthenia":[196],"gravis":[197],"observed":[199,245,327],"pt":[202],"who":[203],"retrospectively":[205],"found":[206],"have":[208,325],"anti-acetylcholine":[209],"receptor":[210],"antibodies":[211],"starting":[214],"No":[216,223],"G3-5":[217],"pneumonitis":[218],"or":[219],"diarrhea":[220],"reported.":[222],"treatment-related":[224],"deaths":[225],"occurred.":[226],"39":[227],"enrolled":[230],"Jul":[233],"1,":[234],"2012,":[235],"efficacy.":[239,290],"responses,":[241],"CR,":[243],"across":[246],"dose":[247],"levels,":[248],"responses":[251,324],"ongoing":[252],"time":[255],"data":[257,278,303],"cutoff.":[258],"Some":[259],"experienced":[262],"prolonged":[263],"SD":[264],"experiencing":[267],"response.":[269],"24-week":[271],"PFS":[272],"50%.":[274],"Analysis":[275],"biomarker":[277],"mandatory":[280],"archival":[281],"tumors":[282],"demonstrated":[283],"correlation":[285],"status":[288,317],"In":[291],"addition,":[292],"response":[293,320],"correlated":[294],"low":[296],"IL-17":[297],"expression":[298],"tumor":[300],"tissue.":[301],"Updated":[302],"will":[304],"be":[305],"presented.":[306],"Conclusions:":[307],"well":[310],"tolerated,":[311],"no":[313],"pneumonitis-related":[314],"deaths.":[315],"PD-L1\u2013positive":[316],"correlates":[318],"MPDL3280A.":[322],"Durable":[323],"further":[335],"is":[337],"warranted.":[338],"Clinical":[339],"trial":[340],"information:":[341],"NCT01375842.":[342]},"counts_by_year":[{"year":2023,"cited_by_count":3},{"year":2022,"cited_by_count":2},{"year":2019,"cited_by_count":3},{"year":2018,"cited_by_count":2},{"year":2017,"cited_by_count":7},{"year":2016,"cited_by_count":12},{"year":2015,"cited_by_count":24},{"year":2014,"cited_by_count":33},{"year":2013,"cited_by_count":10}],"updated_date":"2026-10-30T12:39:25.321706","created_date":"2016-06-24T00:00:00"}